BioMarin price target raised to $108 from $100 at Citi. Citi analyst Robyn Karnauskas raised her price target for Biomarin Pharmaceutical to $108 following the approval of Palynziq. The drug received a broad label and monitoring only for a single dose can accelerate patient uptake, Karnauskas tells investors in a research note. She keeps a Buy rating on BioMarin shares
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.